Evidence for the Presentation of Major Histocompatibility Complex Class I-restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes

Kui Shin Voo, Tihui Fu, Helen Y. Wang, Judy Tellam, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Rong Fu Wang

Research output: Contribution to journalArticlepeer-review

127 Scopus citations

Abstract

The Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) is expressed in all EBV-associated tumors, making it an important target for immunotherapy. However, evidence for major histocompatibility complex (MHC) class I-restricted EBNA1 peptides endogenously presented by EBV-transformed B and tumor cells remains elusive. Here we describe for the first time the identification of an endogenously processed human histocompatibility leukocyte antigen (HLA)-B8-restricted EBNA1 peptide that is recognized by CD8+ T cells. T cell recognition could be inhibited by the treatment of target cells with proteasome inhibitors that block the MHC class I antigen processing pathway, but not by an inhibitor (chloroquine) of MHC class II antigen processing. We also demonstrate that new protein synthesis is required for the generation of the HLA-B8 epitope for T cell recognition, suggesting that defective ribosomal products (DRiPs) are the major source of T cell epitopes. Experiments with protease inhibitors indicate that some serine proteases may participate in the degradation of EBNA1 DRiPs before they are further processed by proteasomes. These findings not only provide the first evidence of the presentation of an MHC class I-restricted EBNA1 epitope to CD8+ T cells, but also offer new insight into the molecular mechanisms involved in the processing and presentation of EBNA1.

Original languageEnglish (US)
Pages (from-to)459-470
Number of pages12
JournalJournal of Experimental Medicine
Volume199
Issue number4
DOIs
StatePublished - Feb 16 2004

Keywords

  • Antigen presentation
  • Cancer vaccines
  • CD8 T cells
  • Immunotherapy
  • MHC class I-restricted peptides

ASJC Scopus subject areas

  • Immunology

Fingerprint

Dive into the research topics of 'Evidence for the Presentation of Major Histocompatibility Complex Class I-restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8<sup>+</sup> T Lymphocytes'. Together they form a unique fingerprint.

Cite this